March 2, 2021

Alterations in serum magnesium levels are presented as a new risk factor in liver disease

Liver disease patients presented altered serum magnesium levels and significantly elevated expression of the CNNM4 protein, a modulator of this cation in the liver Targeted regulation of CNNM4 by GalNac-siRNA technology developed by Silence Therapeutics opens a novel therapeutic window for liver disease The study has been published in the international Journal of Hepatology, one...
Read More